Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. - Wikidata - wikimedia - TriplyDB

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

http://www.wikidata.org/entity/Q37339628

about

Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.Optimization of liposomal topotecan for use in treating neuroblastoma.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.Camptothecin-based nanodrug delivery systems.Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.Renal Cell Carcinoma: Molecular Aspects

P2860

Q28544821-79AA76DE-CE11-482B-B6D4-8CB5D2B7EBB3 Q30101057-C2C4C664-4876-4F9C-B02E-FA58ED45EEF8 Q33416097-412DB924-42BB-4BF0-A88D-863428BC1FA1 Q33775276-D4457369-9A27-4968-883E-C7D7D201EF38 Q37441604-FD364942-D175-4519-9B13-5DC2173F5A18 Q37671842-C8B21A97-BE2C-4DB1-B52A-2FE3835E813B Q38180311-A83FE31D-0960-4BD6-96BB-3CC3A025B1FB Q38777221-FC0BAD26-B84B-49DB-AC94-C0A46A2A1DF6 Q44735229-FD5D4923-CF6D-4B5A-9921-6F37B5DDEFE4 Q47700115-77CD9D46-1996-4E57-A671-721F6132C9BD Q53082813-39FF0686-22C0-4CA2-B738-A3A46BFF942C Q57178229-025FCFBA-05CE-4BB6-8D5E-0AB234F0696D

P2860

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

http://www.wikidata.org/entity/Q37339628

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I dose-escalation study ...... patients with advanced cancer.

@en

Phase I dose-escalation study ...... patients with advanced cancer.

@nl

type

label

Phase I dose-escalation study ...... patients with advanced cancer.

@en

Phase I dose-escalation study ...... patients with advanced cancer.

@nl

prefLabel

Phase I dose-escalation study ...... patients with advanced cancer.

@en

Phase I dose-escalation study ...... patients with advanced cancer.

@nl

P1433

Q37339628-60C1A22B-A1CD-4A54-98E8-BF41A0C8B341

P1476

Q37339628-CAF8A703-D94F-4CF4-8C98-4859BD050122

P2093

Q37339628-008BF1DD-6538-46B6-83B3-9C0E662678AF

Q37339628-09F6E850-5621-49C9-8813-CE6D185B2242

Q37339628-1B9CD56B-DACF-4E47-B877-025756C01953

Q37339628-2DC5E183-6B66-4F0D-8445-0A4AF83C001D

Q37339628-6D5E325A-C7CF-49D8-B481-04770A54C077

Q37339628-8FA84109-7ED6-400C-993E-3162E4BB2E6D

Q37339628-B1C074CC-D894-4D81-BEB7-8B7E7090B684

Q37339628-C0586AAC-0C3A-4B39-8E5D-23DEDDF220B9

Q37339628-C7E7406C-B9A6-4D12-9649-9834BAA661F4

Q37339628-CADA7EA5-49FC-4243-99B0-FB726FC4140C

P2860

Q37339628-134EDA44-F8BC-4AA4-B218-E5107F41EB33

Q37339628-2E1BCA0B-B037-417B-9690-1F4A056CE261

Q37339628-498CE772-2336-4A45-AEE9-EC5E9DC0AEFF

Q37339628-4A1BB18A-26B5-41A2-8AA6-534A2FEDF866

Q37339628-56BC2874-E1B3-4968-A3C1-3096724D3787

Q37339628-598F2C3B-F5D7-49F3-A44A-F9F7978995FD

Q37339628-64195CDD-6949-402E-90FA-DE0E6CEE2569

Q37339628-66CBA1EB-33C1-4196-85F1-EA2666A7C97F

Q37339628-69FEE3A0-57DC-4CB9-9359-920B5EEF3479

Q37339628-7C37B6E0-15C5-4154-BE8E-606E74F09B00

P2888

Q37339628-CC6214B7-785D-4F4B-B65D-5563B41EC370

P304

Q37339628-B2A292D7-873E-4525-927F-D166B13DB430

P31

Q37339628-DAFA2B86-35BF-4DE3-AB75-8F80C16300D8

P356

Q37339628-6F164378-AFA1-4CDF-9888-1827CD98135E

P433

Q37339628-529EEA53-0661-4F1E-954A-43AF58890374

P478

Q37339628-626DBF20-A160-42BD-82E8-BE2A3E5EEE55

P50

Q37339628-432F6E1E-3C42-4D4F-80D4-41CA5F63FAF6

Q37339628-58872599-3E51-4F11-8007-56ED08A1A5D7

Q37339628-D3FC9176-AC59-4F04-963A-3746A851D482

P577

Q37339628-DE9654D3-4FF1-45F3-A4BA-468006BDDFA6

P698

Q37339628-B9F49BE6-DDC0-43A5-BDD6-50841D0D6B6A

P932

Q37339628-C234C743-8288-41C2-AE66-2E1C110FC8A0

P356

S00280-013-2149-2

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I dose-escalation study ...... patients with advanced cancer.

@en

P2093

Aby Buchbinder

http://www.w3.org/2001/XMLSchema#string

Amita Patnaik

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

François M Lokiec

http://www.w3.org/2001/XMLSchema#string

Keyvan Rezaï

http://www.w3.org/2001/XMLSchema#string

Kyriakos P Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Larry J Schaaf

http://www.w3.org/2001/XMLSchema#string

Muralidhar Beeram

http://www.w3.org/2001/XMLSchema#string

Sanaa Tahiri

http://www.w3.org/2001/XMLSchema#string

Saïk Urien

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4

The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

P2888

s00280-013-2149-2

P304

1499-1506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2149-2

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Tanios Bekaii-Saab

P577

2013-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23543270

http://www.w3.org/2001/XMLSchema#string

P932

3839288

http://www.w3.org/2001/XMLSchema#string